Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
ID: 349975Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349975

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-280.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)" aimed at promoting exploratory studies on how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The initiative seeks to investigate the mechanisms through which these agents may affect cancer risk, especially concerning obesity-related cancers, rather than focusing solely on short-term outcomes like weight loss and diabetes management. With a funding ceiling of $275,000 over a two-year period, this opportunity is open to a diverse range of eligible applicants, including various educational institutions and community organizations. Interested parties should submit their applications by January 7, 2027, and can find more information and submission guidelines at the NIH grants website or by contacting grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-280-Full-Announcement.html
    PAR-23-280.html
    The National Cancer Institute (NCI) has released a Notice of Funding Opportunity (NOFO) inviting applications for exploratory studies investigating how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. This initiative focuses on their potential links to thyroid and prostate cancers, given their role in managing obesity and type 2 diabetes. Grant applications, due by various deadlines starting from January 16, 2024, should address mechanistic questions about these agents' effects on cancer risk, immune response, and metabolic changes. The funding limit is $275,000 over two years, with eligibility extending to a wide range of institutions, including higher education and nonprofit organizations. The NCI aims to encourage innovative research that clarifies the relationship between incretin mimetics and cancer mechanisms, aiming to inform clinical practices. Applications must be submitted through specific online platforms and adhere to the detailed submission requirements outlined in the grant announcement, emphasizing compliance to enhance the likelihood of funding.
    Similar Opportunities
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)" aimed at investigating how incretin mimetics, particularly GLP-1 and dual GLP-1/GIP-1 receptor agonists, influence cancer risk. The program seeks to promote preclinical and patient-based studies that explore the mechanisms by which these agents affect cancer, especially in relation to obesity-related cancers, while attracting talented scientists to focus on long-term outcomes rather than short-term effects like weight loss and diabetes. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications encouraged to begin submission starting January 5, 2024, for projects with a funding period of up to five years. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and the opportunity is set to close on January 7, 2027.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)." This grant aims to support innovative, investigator-initiated studies that explore how bariatric surgery influences cancer risk, moving beyond traditional short-term outcomes such as weight loss and diabetes management. Given the rising prevalence of obesity and the increasing number of bariatric surgeries performed in the U.S., this research is crucial for identifying new pathways for cancer prevention. The grant provides funding of up to $275,000 over two years, with applications due by January 16, 2025, and additional cycles available through 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-044.html.
    Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research investigating the mechanisms by which bariatric surgery impacts cancer risk, under the title "Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)." This initiative aims to support studies that explore the long-term effects of bariatric surgery on cancer risk, moving beyond immediate outcomes such as weight loss and diabetes, and considering factors like sex, racial background, and procedure type. With a funding ceiling of $500,000 per year for up to five years, the program encourages innovative research proposals from a diverse range of eligible applicants, including educational institutions and community organizations. Applications are due by January 7, 2028, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-043.html.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity (PAR-23-051) aimed at investigating the mechanistic links between diet, lipid metabolism, and tumor growth and progression. This initiative seeks applications that explore how dietary patterns, particularly high-fat or ketogenic diets, influence cancer cell metabolism and tumor behavior, with a focus on the role of lipids in these processes. The program is designed to bridge the fields of nutrition and molecular metabolism, stimulate research, and develop tools to enhance understanding in this area, while emphasizing collaboration among investigators with expertise in nutrition. Applicants may request up to $500,000 annually for a maximum of five years, with the application deadline set for October 23, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Mechanistic links between diet, lipid metabolism, and tumor growth and progression," under the UH2 Clinical Trial Not Allowed activity code. This initiative aims to support fundamental studies that investigate the molecular mechanisms linking lipid metabolism to tumor growth, with a focus on bridging the fields of nutrition and molecular metabolism. The program is particularly significant as it addresses critical gaps in understanding the relationship between diet and cancer biology. The funding amount is capped at $275,000 over a two-year period, with applications due by October 23, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting exploratory research into the human microbiome's role in anti-tumor immunity. This initiative seeks to elucidate the mechanisms by which specific microbes or their metabolites influence immune responses and inflammation related to tumor formation, with a focus on identifying novel molecular targets for cancer prevention strategies. Eligible applicants include a wide range of organizations, such as educational institutions, nonprofits, and tribal governments, with funding available up to $275,000 for two-year projects. Interested parties should submit their applications by January 7, 2025, and can find additional information at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)." This grant aims to support translational research that justifies later-phase therapeutic discovery and development efforts related to diseases such as obesity, diabetes, digestive disorders, and kidney diseases. The initiative encourages innovative research on novel small molecules and biologics, with a focus on therapeutics that significantly improve or differentiate from existing treatments. NIH anticipates awarding 3-4 grants annually, with budgets ranging from $250,000 to $300,000 per project for up to five years. Interested applicants must submit their proposals by January 7, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. Additional details can be found at http://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html.